Beta-Amyloid and tau accumulation in Alzheimer’s disease Drug development for Alzheimer’s disease (AD) continues to face significant challenges, largely due to the limited availability of reliable biomarkers and the high risk of trial failure.
Why is harmonisation of imaging protocols important in Alzheimer's disease clinical trials? Harmonisation of imaging protocols is crucial in Alzheimer's disease clinical trials for several reasons. Firstly, it ensures consistency and accuracy across different trial sites, which is essential for reliable data collection and analysis.
Innovation Trends in AD Research –the shift to increasingly individualised trial design, therapeutics and care. Alzheimer’s disease (AD) research is entering a new phase of innovation, highlighted by a number of advances presented at recent conferences such as CTAD 2024 in Madrid and AD/PD 2025 in Vienna.
Imaging: Advancing Biomarker Research for Alzheimer's Disease Diagnosis In an article published in the latest edition of the Journal for Clinical Studies, IXICO’s Chief Scientific Officer Robin Wolz outlines how data from the landmark Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation (GAP) and supported by IXICO as imaging partner, can help better understand the…
This week we will be at the ADPD 2025 International Conference talking about some of our latest biomarker research. Specifically, we are presenting an AI-based approach to differentiate different types of dementia from magnetic resonance imaging (MRI).
International Women's Day (IWD) has been around for over a hundred years, as have many of the issues still impacting women's advancement. Since 1911, IWD belongs to all who care about women's equality, celebrating women's achievement, raising awareness about discrimination and taking action to forge gender parity.
Alzheimer's disease is a complex neurodegenerative disorder that affects millions of people worldwide. While there is no cure for the disease, ongoing research efforts have led to significant advancements in our understanding of the underlying mechanisms that drive the disease.
Multiple Sclerosis (MS) is an unpredictable neurological condition which affects the brain and spinal cord, potentially causing a wide range of symptoms including problems with vision, arm or leg movements, sensation, and balance. Multiple Sclerosis (MS) is the most common autoimmune disorder of the Central Nervous System (CNS), affecting around 2.
CHDI’s 17th Annual Therapeutics Conference: Event ReviewBy Ronald Ramos (Senior Director, Business Development) and Kirsi Kinnunen (Senior Biomarker Scientist) CHDI’s 17th Annual HD Therapeutics Conference finally returned to a full, in-person event for the first time since 2020.
The Global Alzheimer's Platform Foundation’s GAP-Net Site Optimization Conference 2022 gave all participants an update on the important Bio-Hermes trial which is going very well. This year’s conference was a highly collaborative event with many interesting presentations and discussions on issues related to research in Alzheimer’s Disease.
1-10 of 22 results